Aegerion

Aegerion Pharmaceuticals is a biopharmaceutical company dedicated to the development and commercialization of innovative therapies for patients with debilitating rare diseases. The company has a diversified commercial portfolio of rare disease therapies which includes MYALEPT® and JUXTAPID®. Aegerion’s parent company, Novelion Therapeutics, seeks to advance its portfolio of rare disease therapies by investing in science and clinical development. Novelion is currently developing zuretinol acetate for the treatment of inherited retinal disease caused by underlying mutations in RPE65 or LRAT genes.